Artwork
iconShare
 
Manage episode 519048421 series 3696834
Content provided by Brandon Li. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Brandon Li or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
The future of psychedelic medicine lies in non-hallucinogenic compounds that could revolutionize treatment for neurological conditions while avoiding the complexity of traditional psychedelic therapy.

In this episode of Power to the Patients, host Brandon Li speaks with Dr. Chris Witowski, CEO and Co-Founder of Psilera, to explore the emerging field of non-hallucinogenic psychedelic compounds and their potential applications in treating neurodegenerative conditions, particularly frontotemporal dementia (FTD).

What You'll Learn:
- How non-hallucinogenic compounds could deliver the benefits of psychedelics without the challenges of traditional psychedelic therapy

- Why neurodegeneration presents a unique opportunity for psychedelic medicine, particularly in addressing mood disorders and cognitive decline

- The science behind neuroplasticity and its potential role in treating neurodegenerative conditions

- How biomarkers in neurological conditions provide clearer efficacy measures compared to psychiatric applications

- Why the traditional psychedelic therapy model may not be suitable for neurodegenerative patients

- The potential for combining traditional psychedelics with non-hallucinogenic maintenance doses for optimal patient outcomes

- How new diagnostic tools and blood tests are revolutionizing patient identification in neurodegenerative conditions

- Why the intersection of natural product chemistry and psychedelic medicine creates new therapeutic possibilities

About the Guest:

Dr. Chris Witowski is the CEO and Co-Founder of Psilera, specializing in the development of non-hallucinogenic psychedelic compounds for neurological conditions. With a background in natural products chemistry and a PhD focused on drug discovery from natural sources, he has extensive experience in pharmaceutical development and previously served as Chief Scientific Officer at AltMed.


Episode Resources:
  continue reading

42 episodes